Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 185Neoplasms 178Carcinoma, Non-Small-Cell Lung 162Prostatic Neoplasms 114Colorectal Neoplasms 111Lung Neoplasms 94Ovarian Neoplasms 85Neoplasm Metastasis 80Multiple Myeloma 75Pancreatic Neoplasms 73Leukemia, Myeloid, Acute 68Endometrial Neoplasms 53Stomach Neoplasms 49Squamous Cell Carcinoma of Head and Neck 48Melanoma 48Lymphoma 46Glioblastoma 45Recurrence 44Carcinoma, Renal Cell 44Urinary Bladder Neoplasms 42Carcinoma, Hepatocellular 41Brain Neoplasms 41Precursor Cell Lymphoblastic Leukemia-Lymphoma 40Sarcoma 38Lymphoma, Non-Hodgkin 36Leukemia, Lymphocytic, Chronic, B-Cell 36Glioma 36Hematologic Neoplasms 35Small Cell Lung Carcinoma 34Esophageal Neoplasms 33

Interventions

irinotecan sucrosofate 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Advanced Rectal Cancer × 30 days × Clear all
NCT07281157 2026-06-03

Liposomal Irinotecan, Capecitabine and Enlonstobart With Short-Course Radiotherapy for Locally Advanced Rectal Cancer

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Recruiting
30 enrolled
Gastrointestinal

Advanced Rectal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡